Table 7.
Clinico-Pathologic Features According to BRAFV600E Status in 36 Patients Whose Primary Tumor was Genotyped
| BRAF positive | BRAF negative | pa | |
|---|---|---|---|
| Age | |||
| <45 | 7 (25%) | 5 (62.5%) | 0.086 |
| >45 | 21 (75%) | 3 (37.5%) | |
| Gender | |||
| Male | 11 (39%) | 1 (12.5%) | 0.2 |
| Female | 17 (61%) | 7 (87.5%) | |
| Primary tumor size | |||
| ≤1.5 cm | 12 (43%) | 4 (50%) | 1 |
| >1.5 cm | 16 (57%) | 4 (50%) | |
| PTC subtypes | |||
| Tall cell (n=14) | 14 (50%) | 0 | 0.01b |
| Classical (n=19) | 13 (46%) | 6 (75%) | |
| Infiltrative FVPTC (n=2) | 0 | 2 (25%) | |
| Microcarcinoma, infiltrative (n=1) | 1 (4%) | 0 | |
| No. of positive nodes | |||
| ≤3 | 10 (36%) | 1 (12.5%) | 0.388 |
| >3 | 18 (64%) | 7 (87.5%) | |
| Extra-nodal extension (n=34)c | |||
| Yes | 10 (37%) | 2 (40%) | 1 |
| No | 17 (63%) | 5 (60%) | |
| Size of largest positive node (n=35)d | |||
| ≤1 cm | 14 (51%) | 1 (14%) | 0.1 |
| >1 cm | 13 (49%) | 7 (86%) | |
| Size of largest metastatic focus (n=35)d | |||
| ≤1 cm | 15 (56%) | 2 (25%) | 0.2 |
| >1 cm | 12 (44%) | 6 (75%) | |
| Vascular invasion | |||
| Present | 0 | 1 (12.5%) | 0.22 |
| Absent | 28 (100%) | 7 (87.5%) | |
| ETE | |||
| Extensive | 18 (64%) | 4 (50%) | 0.6 |
| Focal | 2 (7%) | 3 (37.5%) | |
| None | 8 (29%) | 1 (12.5%) | |
a
Fisher's exact test.
b
Tall cell vs. nontall cell.
c
In 2 cases, extra nodal extension could not be evaluated.
d
In one individual, the size of the metastatic node and largest metastatic focus could not be assessed.